AbbVie announced that Health Canada has approved its Rinvoq® (upadacitinib, 15mg), an oral once-daily selective and reversible JAK inhibitor for the treatment of Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation who have had an inadequate response to a biologic disease modifying anti-rheumatic drug or when use of those therapies is inadvisable. It is the first and only JAK inhibitor approved for the full spectrum of axial spondyloarthritis.
This comes only a few weeks after the EC approved Rinvoq® for Chron’s disease in Europe.